Abstract | BACKGROUND: METHODS: LNCaP cells transfected with antisense AR RNA retroviral vector pL-AR-SN were designated as LNCaPas-AR. LNCaP cells containing empty vector pLXSN served as LNCaPNeo. LNCaP and LNCaPNeo were taken as controls. In vitro cell growth assay, proliferative cells of LNCaP and tranfected LNCaPs were counted by typan staining when they cultured with synthetic androgen R1881, 17beta-estradiol, and progesterone, respectively. RESULTS: Growth of LNCaPas-AR was inhibited significantly (P < 0.05) compared with that of LNCaP and LNCaPNeo at 1 nmol/L R1881, 10 nmol/L 17beta-estradiol, and 1 nmol/L progesterone, respectively. No difference was seen between LNCaP and LNCaPNeo (P > 0.05). Microscopic observation showed that LNCaP and LNCaPNeo cells grew well, but only few LNCaPas-AR cells were alive. CONCLUSIONS: Our observations indicate that antisense AR RNA retroviral vector pL-AR-SN could change androgen-independent characteristics of LNCaP cells, which might shed some novel insights into the treatment of androgen-independent prostate cancer.
|
Authors | Jun Jiang, Luo-fu Wang, Yu-hua Fang, Feng-shuo Jin, Wen-sheng Jin |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 117
Issue 5
Pg. 684-8
(May 2004)
ISSN: 0366-6999 [Print] China |
PMID | 15161534
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androgen Receptor Antagonists
- RNA, Antisense
- Receptors, Androgen
- Metribolone
- Progesterone
- Estradiol
|
Topics |
- Androgen Receptor Antagonists
- Cell Division
(drug effects)
- Cell Line, Tumor
- Dose-Response Relationship, Drug
- Estradiol
(pharmacology)
- Humans
- Male
- Metribolone
(antagonists & inhibitors, pharmacology)
- Progesterone
(antagonists & inhibitors, pharmacology)
- Prostatic Neoplasms
(pathology, therapy)
- RNA, Antisense
(therapeutic use)
- Receptors, Androgen
(genetics)
|